Article
Author(s):
The FDA has issued 14 warning letters and 4 online advisory letters to US-based companies illegally selling more than 65 products with fraudulent claims that they cure cancer.
The FDA has issued 14 warning letters and 4 online advisory letters to US-based companies illegally selling more than 65 products with fraudulent claims that they cure cancer.
These products are both marketed and sold—–mostly on websites or social media platforms––without FDA approval, according to a press release.
Consumers should not use these or similar unproven products because they may be unsafe and could prevent a person from seeking an appropriate and potentially lifesaving cancer diagnosis or treatment,” Douglas W. Stearn, director of the Office of Enforcement and Import Operations, FDA’s Office of Regulatory Affairs, said in the release. “We encourage people to remain vigilant whether online or in a store, and avoid purchasing products marketed to treat cancer without any proof they will work. Patients should consult a health care professional about proper prevention, diagnosis, and treatment of cancer.”
Products cited in the warning letters include topical creams, ointments, pills, drops, syrups, teas, and diagnostics. Additionally, the products carry unproven claims that they prevent, reverse, or cure cancer; inhibit cancer cells or tumors; or other similar anti-cancer claims.
The FDA has requested responses from the 14 companies on how the violations will be corrected, according to the release. If the companies fail to comply, it may result in legal action, including product seizure, injunction, and/or criminal prosecution.
Over the past decade, the FDA has issued more than 90 warning letters to companies marketing hundreds of fraudulent products that made unfounded cancer claims. Although most of the companies have stopped selling these products, there are still unsafe and unapproved products that continue to be sold directly to consumers.
Health care professionals and consumers are encouraged to report adverse events associated with these types of products to the FDA’s MedWatch Program.
The following companies and products received warning letters:
The following 4 companies and products received online advisory letters: